# Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

> **NCT07450664** · — · ENROLLING_BY_INVITATION · sponsor: **Soleno Therapeutics, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** VYKAT XR

## Key facts

- **NCT ID:** NCT07450664
- **Lead sponsor:** Soleno Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-26
- **Primary completion:** 2028-03
- **Final completion:** 2028-03-02
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07450664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07450664, "Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07450664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*